Dr. Frank Kung is a founding General Partner of Vivo Ventures, LLC (formerly BioAsia Investments), a life sciences focused venture capital firm formed in 1996 with over $650M under management. Vivo Ventures is currently making investments from its $275M sixth fund into promising biotechnology and life science companies. Its portfolio includes more than 60 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices Vivo Ventures is headquartered in Palo Alto , CA , it established its offices in Shanghai 2 years ago.
Dr. Kung received his B.S. in chemistry from the National Tsing Hua University in Taiwan , his Ph.D. in molecular biology and M.B.A. from the University of California , Berkeley . He received the Best Use of Technology Award from the Governor of California, the Entrepreneur of the Year Awards from Ernst and Young, and the Asian Business League.

Since 2003, Dr. Wayne Huang has been the managing director and CTO of the TMT sector for ChinaEquity, a VC and investment banking firm founded by former Morgan Stanley investment banker and Swiss bankers.  Leveraging his Motorola executive and startup experience, he contributed to portfolio companies in post investment services.  He has also served as an advisor to CTO offices in numerous US companies.  While doing this, he built up a strong reputation as a sought after management consultant in technology acquisitions advisory and post M&A integration services.
In early 2000, he ran his start up eAnywhere for four years, first competing with Siemens’s module product in China and then achieving No.1 market share through partnership with Yulong (HKEX: 2369) as China Unicom qualified vendor, then partnering with Telular (NASDAQ:WRLS ) and together entering US commercial public safety market  as qualified Lucent vendor before successful acquisition in 2003.

Mr. He joined OmniVsion as Senior Engineer in 1995, right after the company’s inception. Mr. He soon moved into management, serving as Design Manager and Director. In 2001, Mr. He was promoted to Vice President of Core Technologies, and in August 2006, become OmniVision’s Chief Operating Officer. Mr. He manages the operation, MIS, sales, marketing, and directs OmniVision’s sensor array R&D for both analog and digital CameraChip products. Mr. He’s engineering and management skills ensure the continuing technological advancement of OmniVision products. In November of 2006, Mr. He was appointed to the OmniVision Board of Directors. Mr. He holds a bachelor and master degree in Electrical Engineering from Tsinghua University in Beijing and holds over 20 US patents.

Dr. Xuecheng Jin is the Vice President of IC Engineering at iWatt Inc, a fables semiconductor startup company in Silicon Valley of California, and is responsible for the company’s analog and mixed signal IC and power conversion technology, with its products volume shipped into leading cellular phone manufacturers. Before that, he is the co-founder and chief technology officer at Simple Silicon Inc (acquired by iWatt Inc in 2006), where his leadership and technical contribution is instrumental to establish the company’s world-class portfolio of advanced high definition video analog front-end technology which has been widely adopted by the HDTV industry. His previous experiences include a project manager at BitBlitz Communications Inc (acquired by Intersil in 2004), a venture funded startup company in the Silicon Valley that designs and manufactures high-speed physical layer devices using conventional CMOS technology; a senior analog design engineer at Integrated Telecom Express Inc (NASDAQ IPO in 2000), an ADSL broadband solution startup in the Silicon Valley; and an associate research fellow at Texas Instruments, the leadership analog and mixed signal semiconductor company.

Dr. Roawen Chen joined Marvell Semiconductor, Inc, in 2000. Prior to returning to this position, Dr. Chen also served as Vice President and General Manger of the Communications and Computing Business Unit (CCBU). He joined Marvell as the Manager of Manufacturing Technology in May 2000, and was promoted to Director and Sr. Director of Foundry Operations, in 2001 and 2003, respectively. In those roles he was responsible for foundry business operations and engineering operations. Prior to Marvell, Dr. Chen held technical positions in TSMC-USA and Intel Corp. Dr. Chen holds a Bachelor of Science degree in Physics from National Tsing-Hua University and a PhD degree in Electrical Engineering and Computer Science from University of California at Berkeley.

Mr. Fu is currently Vice President, Business Development at Johnson & Johnson, heading up J&J’s west coast pharmaceuticals business development group.  He has 12 years of business development and management consulting experience in the biopharmaceutical and healthcare industries.  Prior to J&J he held managerial positions with consulting firm McKinsey & Company in their west coast biotech practice and Becton Dickinson, a leading medical device company.  Tao has a proven track record in negotiating all types of business development transactions and has executed 25+ deals, including the sales of Scios Inc. to Johnson & Johnson for $2.6 billion in 2003 and the US license of Bayer's cardiovascular product rivaroxaban, one of the largest pharmaceutical licensing deal in 2005.  Tao also has extensive experience in developing business and product strategies and leading corporate financial planning in the biopharmaceutical industry.  He is a Chartered Financial Analyst (CFA) and holds degrees of MBA in Finance from Vanderbilt University, MS in Biology from the University of Rochester and BS in Biological Sciences from Tsinghua University.